Progression
|
Healthy to infectionc
|
HPV-16
|
0.000175–0.003148
|
0.0001426–0.00761
|
Calibrated
|
HPV-18
|
0.0004–0.000789
|
0.000102–0.00168
|
Other HR HPV
|
0.000206–0.004038
|
0.0001703–0.00911
|
LR HPV
|
0.000958–0.018412
|
0.00069–0.0537
|
HPV DNA to CIN1d
|
HR-16 HPV
|
0.005194–0.00901
| |
[7]
|
HR-18 HPV
|
0.002793–0.004845
| | |
HR-other HPV
|
0.007693–0.013345
| | |
LR-HPV
|
0.002397–0.001222
| | |
Proportion (%) of women who transition directly from HPV DNA to CIN2,3
|
HR-16 HPV
|
0.64
| |
[7]
|
HR-18 HPV
|
0.975
| | |
HR-other HPV
|
0.966
| | |
LR-HPV
|
0.98
| | |
CIN 1 to CIN 2,3d
|
HR-16 HPV
|
0.00951–0.012363
| |
[7]
|
HR-18 HPV
|
0.0051–0.00663
| | |
HR-other HPV
|
0.00747–0.009711
| | |
LR-HPV
|
0.000149–0.000222
| | |
CIN 2,3 to local cancer
|
HR-16 HPV
|
0.000151–0.00906
| |
[7]
|
HR-18 HPV
|
0.000264–0.01584
| | |
HR-other HPV
|
0.000199–0.01194
| | |
Local to regional invasive cancer
|
0.0200
| |
[7]
|
Regional to distant invasive cancer
|
0.0250
| | |
Regression
| |
HPV DNA to normal
|
HR-16 HPV
|
0.09089
| |
[7]
|
HR-18 HPV
|
0.09089
| | |
HR-other HPV
|
0.09272
| | |
LR-HPV
|
0.09699
| | |
CIN 1 to normale
|
HR-16 HPV
|
0.03782
| |
[7]
|
HR-18 HPV
|
0.03782
| | |
HR-other HPV
|
0.04575
| | |
LR-HPV
|
0.01708
| | |
CIN 2,3 to normalf
|
HR-16 HPV
|
0.000798–0.000455
| |
[7]
|
HR-18 HPV
|
0.003556–0.011938
| | |
HR-other HPV
|
0.002926–0.009823
| | |
LR-HPV
|
0.001904–0.006392
| | |
Other
| |
Immunity (%) (HR-HPV types only)g
|
HR-16 HPV
|
0.66
| |
[7]
|
HR-18 HPV
|
0.86
| | |
HR-other HPV
|
0.59
| | |
Annual probability of symptom detectionh
|
Local invasive cancer
|
0.33
| |
[7]
|
Regional invasive cancer
|
0.60
| | |
Distant cancer
|
0.9
| | |
Proportion of cancer patient receiving the treatment
|
Local cancer
|
100 %
| |
Calibrated
|
Regional cancer
|
80 %
| | |
Distant cancer
|
70 %
| | |
Age-specific 5-year survival proportion after diagnosis and treatment (%)i
|
Local cancer
|
0.29–71 %
| |
Calibrated
|
Regional cancer
|
0.24–78 %
| |
Age-specific monthly probability of death
|
Complication of local cancer treatment
|
0.012–0.037
| |
Calibrated
|
Complication of regional cancer treatment
|
0.0098–0.028
| |
Distant cancer
|
0.28–0.83
| |